🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

MK-3475-669

Phase 3 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL for Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies is a Phase 3 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Incyte Biosciences Distribution B.V.
Indication
Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials